FAQ/Help |
Calendar |
Search |
Today's Posts |
|
12-04-2016, 04:02 PM | #1 | ||
|
|||
Member
|
Just found this on Veritas. Know nothing about PRX002.
First-in-human assessment of PRX 2, an anti-α-synuclein monoclonal antibody, in healthy volunteers. - PubMed - NCBI |
||
Reply With Quote |
12-04-2016, 04:05 PM | #2 | ||
|
|||
Member
|
Just found this on ******* (correction). Know nothing about PRX002.
First-in-human assessment of PRX 2, an anti-α-synuclein monoclonal antibody, in healthy volunteers. - PubMed - NCBI |
||
Reply With Quote |
12-04-2016, 04:07 PM | #3 | ||
|
|||
Member
|
|
||
Reply With Quote |
12-04-2016, 04:25 PM | #4 | ||
|
|||
Member
|
Quote:
Last edited by Tupelo3; 12-04-2016 at 06:00 PM. |
||
Reply With Quote |
12-05-2016, 08:10 AM | #5 | ||
|
|||
Junior Member
|
Not sure if this was posted before, but this was a good story about how the MJFF mishandled this with GU:
Parkinson's disease study caught in feud involving Fox Foundation And a response from the MJFF CEO on this matter: Fox Foundation committed to moving rapidly and carefully on Parkinson’s drug trial - The Boston Globe |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Nilotinib - lastest update - not the best news | Parkinson's Disease | |||